Rivia raised USD 15 million in an oversubscribed Series A led by Earlybird Venture Capital, with Defiant and existing investors Speedinvest, Amino Collective and Nina Capital participating. The Zurich company is developing software that brings clinical trial data into a shared structure, helping biotechnology companies analyse studies and coordinate their work.
Its platform harmonises records from different vendors and maps them to trial-specific models covering protocols, visits and endpoints. Rivia says its growing library of these models supports workflows and AI tools that help teams examine patient data and identify issues without repeatedly assembling information by hand.
